Practitioner's Docket No. U 015759-8

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application of	
	nventor(s)
or	
Title	e of invention
	OR
n re application of: Ekaterina Vladimirovna B	
erial No.: 10/533,781	Group No.:
iled: October 19, 2005 for: FLUORESCENT PROTEINS FROM USING SAME	Examiner: COPEPODA SPECIES AND METHODS FOR
Commissioner for Patents	:
P. O. Box 1450 Alexandria, VA 22313-1450	
WITHIN THREE I	IATION DISCLOSURE STATEMENT MONTHS OF FILING OR I OFFICE ACTION (37 C.F.R. 1.97(b))
(When using Express Mail, the Express Mail o	NDER 37 C.F.R. 1.8(a) and 1.10* Express Mail label number is mandatory; certification is optional.)
hereby certify that, on the date shown below, this corres	pondence is being:
	MAILING
deposited with the United States Postal Service in an of Alexandria, VA 22313-1450.	envelope addressed to the Commissioner for Patents, P. O. Box 1450,
37 C.F.R. 1.8(a)	37 C.F.R. 1.10*
with sufficient postage as first class mail.	as "Express Mail Post Office to Addressee" Mailing Label No
TRA	ANSMISSION
1 transmitted by facsimile to the Patent and Trademark	c Office. to (571)-273-8300
Date: November 23, 2005	Signyture CLIFFORD/I. MASS (type or prifit yame of person certifying)
certificate of mailing or transmission under § 1.8 c	in a patent term adjustment calculation, although the date on any continues to be taken into account in determining timeliness. See § dressee" (§ 1.10) or facsimile transmission (§ 1.6(d) for the reply to

(Transmittal of Information Disclosure Statement Within Three Months of Filing or Before Mailing of First Office
Action—page 1 of 3) 6-3

be accorded the earliest possible filing date for patent term adjustment calculations.

<i>(1)</i>	Each U.S. patent listed in an information disclosure statement must be identified by inventor, patent number, and issue date.
(2)	Each U.S. patent application published listed in an information disclosure statement shall be identified by applicant, patent application publication number, and publication date.
(3)	Each U.S. application listed in an information disclosure statement must be identified by the inventor, application number, and filing date.
(4)	Each foreign patent or published foreign patent application listed in an information disclosure statement must be identified by the country or patent affice which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application.
(5)	Each publication listed in an information disclosure statement must be identified by publisher, author (fi any), title, relevant pages of the publication, date, and place of publication.

NOTE: 37 C.F.R. 1.98(b):

WARNING:

NOTE: The "filing date of a national application" under 37 C.F.R. I. 97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark Office, the filing is defined in 37 C.F.R. I. 33(b) as "the date on which: (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drowing required by § 1.81(a) are filed in the Patent and Trademark Office in the man of the actual inventor or inventors as required by § 1.41." 37 C.F.R. 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by \$ 1.5 U.S. C. § 371(c) within the periods set forth in § 1.94 or § 1.495. 35 U.S. C. § 371(c) requires the filling of the following: (1) the national fee: (2) a copy of the international application, unless already set by the International Bureau, and an English translation if filed in another language; (3) amendments under PCT Article 19, with a translation into English fy made in another language; (4) an oath or declaration; and (3) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language; 37 C.F.R. 1,97(b)(2).

C.F.R. § 1.97(f).

No extension of time can be had under 37 C.F.R. § 1.36 (a) or (b) for filing an IDS. 37

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filed date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. 1.97(b).

NOTE:	"No certification or fee is due when the filing is made within the above time period. It is advisable to ensure that
	no Office action has been mailed if the disclosure statement is delayed until after three months from filing."

NOTE: "An Information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a milling faccompanied by a properly executed certificate of mailting water 37 C.F.R. 1.8. or Express Mail certificate under 37 C.F.R. 1.10. An office action in Statice of April 20 1) 1992 (1138 O.S. 37-41, 39).

NOTE: "The term 'national application' includes continuing applications (continuations, divisions, continuationsin-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 OG, 37-41, 392) NOTE: "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 C.F.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(II)). Thus, if an application was filled on Jan 1. and the first Office action on the merits was not maided until six months later on July 1, the examiner would be required to consider any proper information disclosure statement filed prior to July 1. "Notice of April 20, 1992 (1/18) CG, 37-41, 39).

WARNING: "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 3 F.C.F.R. J. 97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (114) O.G. 63). But see § 103(b) and (c), limited suspension of action in a continued prosecution application (CPA) filed under § 1.53(d) and in a request for continued examination (RCE) under § 1.14.

If a fee is required, please charge deposit account 12-0425.

Reg. No. 30,086

Tel. No.: (212) 708-1890

Customer No.: 00140

GONATURE OF PRACTITIONER

CLIFFORD J. MASS
(type or print name of practitioner)

P.O. Address

c/o Ladas & Parry LLP 26 West 61st Street New York, N.Y. 10023

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ekaterina Vladimirovna BARSOVA, et al

Serial No.: 10/533,781

Group No. - -

Filed: October 19, 2005

Examiner: - -

For: FLUORESCENT PROTEINS FROM COPEPODA SPECIES AND METHODS FOR

USING SAME

Attorney Docket No.: U 015759-8

Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the attached references which are also listed on the attached Form PTO-1449.

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10* (When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.) I hereby certify that, on the date shown below, this correspondence is being: Ø deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. 37 C.F.R. 1.8(a) Ø with sufficient postage as first class mail. as "Express Mail Post Office to Addressee Mailing Label No. TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office. to (571)-273-8300

*WARNING:

Date: November 23, 2005

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b). "Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Signature

CLIFFORD J. MASS (type or print name of person certifying)

(Information Disclosure Statement Short Form-page 1 of 1) 6-1a

Respectfully Submitted,

CLIFFOND MASS C/O LADAS AND PARRY LLP 26 WEST 61ST STREET NEW YORK, NY 10023 REG. NO. 30,086; (212) 708-1890

FORM PTO-1449	U. S DEPARTMENT OF COMMERCE		ATTY. DOCKET NO.		SERIAL NO.				
	OFFICE		U 015759-8		10/533,781				
	INFORMATION DISCLOSURE			APPLICANT					
STATEMENT BY APPLICANT			Ekaterina Vladimirovna BARSOVA et al.						
(Use several sheets if necessary)			FI	ILING DATE		GROUP			
				OBER 19, 2005					
	FOREIGN	N PATENT I	OCUME	NTS					
	D0CUMENT NUMBER	DAT	·c	COUNTR	v	TRANSLATION			
			ь	COUNTRY		YES	NO		
AA	00/02997	01/2000		wo					
AB	00/03246	01/2000		wo					
AC	00/17643	03/2000		wo					
AD	00/17624	03/2000		wo					
AE	00/26408	05/2000		wo					
AF	00/34318	06/2000		wo					
AG	01/27150	04/2001		wo					
AH	02/059309	08/2002		wo					
AI	2003/062270	07/2003		wo					
	OTHER ART (Includi	ing Author, T	itle, Date	, Pertinent Dates, Etc	.)				
AJ	Lippincott-Schwarts, et al. "Development and Use of Fluorescent Protein Markers in Living Cells." Science (2003) Vol. 300, pp 87-91								
AK	PubMed Abstract. Chalfie, M., et al. "Green Fluorescent Protein as a Marker for Gene Expression." Science (1994) Vol. 263 (5148), pp 802-805								
AL	Heim, R., et al. "Wavelength Mutations and Positranslational Autoxidation of Green fluorescent Protein." Proc. Natl. Acad. Sci. USA (1994) Vo. 91, pp 12501-12504								
AM	PubMed Abstract . Rizzuto, R., et al. "Chimeric Green Fluorescent Protein as a Tool for Visualizing Subcellular Organelles in Living Cells." Curr. Biol. (1995) Vol. 5 (6) pp 635-642								
AN	PubMed Abstract. Kaether, C., et al. "Visualization of Protein Transport Along the Secretory Pathway Using Green Fluorescent Protein." Febs. Lett. (1995) Vol. 369 (2-3) pp 267-271								
AO	PubMed Abstract . Haas, J., et al. "Codon Usage Limitation in the Expression of HIV-1 Envelope Glycoprotein." Curr. Biol. (1996) Vol. 6(3) pp 315-324								
AP	Yang, T., et al. "Optimized Codon Usage and Chromophore Mutations Provide Enhanced Sensitivity with the Green Fluorescent Protein." Nucl. Acids Res. (1996) 24, pp 4592-4594								
AQ	Matz, M., et al. "Fluorescent Proteins from Nonbioluminescent Anthozoa Species." Nature Biotechnology (1999) Vol. 17, pp 969-973								
AR	Matz, M., et al. "Family of the Green Fluorescent Protein: Jorney to the End of the Rainbow." <i>Bioessays</i> (2002) Vol. 24. No. 10, pp 953-959								
AS	Xia, N., et al. "Bioluminescence of Aequorea Macrodactyla, a Common Jellyfish Species in the East China Sea." Marine Biotechnology (2002) Vol. 4, pp 155-162								
AT	Gurskaya, N., et al. "A Colourless Green Fluorescent Protein Homologue from the Non-Fluorescent Hydromedusa Aequorea Coerulescens and Its Fluorescent Mutants." Biochem. J. (2003) 373, pp 403-408								
EXAMINER	EXAMINER				DATE CONSIDERED				
	itial if citation considered, whether or	not citation i	L		609; Draw l	line through cit	ation if		
no	ot in conformance and not considered.	Include copy	of this fo	orm with next commu	nication to	applicant.			

FORM PTO-1449 U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) ATTY. DOCKET NO. SERIAL NO. U 015759-8 10/533,781 Ekaterina Vladimirovna BARSOVA et al. FILING DATE GROUP

		U.S.	PATENT DOCUME	NTS	
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE II
	AA	6,066,476	05/2000	Tsien et al.	
	AB	6,020,192	02/2000	Muzyczka et al.	
	AC	5,985,577	11/1999	Bulinski	
	AD	5,976,796	11/1999	Szalay et al.	
	AE	5,968,750	10/1999	Zolotukhin et al.	
	AF	5,968,738	10/1999	Anderson et al.	
	AG	5,958,713	09/1997	Thastrup et al.	
	AH	5,919,445	07/1999	Chao	
	AI	5,874,304	02/1999	Zolotukhin et al.	
	AJ	5,843,746	12/1998	Tatsumi et al.	
	AK	5,700,673	12/1997	McElroy et al.	
	AL	5,674,713	10/1997	McElroy et al.	
	AM	5,618,722	04/1997	Zenno et al.	
	AN	5,418,155	05/1995	Cormier et al.	
	AO	5,330,906	07/1994	Kajiyama et al.	
	AP	5,229,285	07/1993	Kajiyama et al.	
	AQ	5,221,623	06/1993	Legocki et al.	0
`	AR	5,182,202	01/1993	Kajiyama et al.	
	AS	6,008,373	12/1999	Waggoner et al.	
	AT	5,998,146	12/1999	Latva et al.	
	AU	5,981,200	11/1999	Tsien et al.	
	AV	5,945,526	08/1999	Lee et al.	
	AW	5,945,283	08/1999	Kwok et al.	
	AX	5,911,952	06/1999	Tsuji	
	AY	5,869,255	02/1999	Mathies et al.	
	AZ	5,866,336	02/1999	Nazarenko et al.	

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER:

FORM PTO-1449 U. S DEPARTMENT OF COMMERCE			ATTY. DOCKET NO.			SERIAL NO.		
PATENT AND TRADEMARK OFFICE				U 015759-8			10/533,781	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT				
				Ekaterina Vladimirovna BARSOVA et al.				ıl.
(Use several sheets if necessary)			FILING DATE		GROUP			
				oct	OBER 19, 2005			
		U.S. I	ATENT DO	CUMEN	TS			
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE		NAME		FILING DATE IF APPROPRIATE	
	AA	5,863,727	01/1999		Lee et al.			
	AB	5,728,528	03/1998		Mathies et al.			
	AC	5,707,804	01/1998		Mathies et al.			
	AD	5,688,648	11/1997		Mathies et al.			
	AE	5,439,797	08/1995		Tsien et al.			
	AF '	5,989,835	11/1999		Dunlay et al.			
	AG	6,130,313	10/2000		Li et al.			
	AH	5,972,638	10/1998		Burlage et al.			
	AI	5,824,485	10/1998		Thompson et al.			
	AJ	5,650,135	07/1997		Contag et al.			
	AK	5,491,084	08/1998		Chalfie et al.			
	AL	5,795,737	08/1998		Seed et al.			
		FOREIG	N PATENT I	осим	ENTS			
		D0CUMENT					TRANSLATION	
		NUMBER	DATE		COUNTRY		YES	NO
	AM							
	AN							
~	AO							
	AP							
	ОТ	HER ART (Includ	ing Author, T	Title, Dat	e, Pertinent Dates, Etc	.)		
	AQ							
	AR							
	AS							
EXAMINER				DATE	CONSIDERED			
EXAMINER:	Initial if citation not in conforma	considered, whether or nce and not considered.	not citation i Include copy	s in conf	ormance with MPEP 6	09; Draw l	line through cit applicant.	ation if